Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1–98

Autor: Kevin H. Kensler, Meredith M. Regan, Yujing J. Heng, Gabrielle M. Baker, Michael E. Pyle, Stuart J. Schnitt, Aditi Hazra, Roswitha Kammler, Beat Thürlimann, Marco Colleoni, Giuseppe Viale, Myles Brown, Rulla M. Tamimi

Publikováno v: Breast Cancer Research, Vol 21, Iss 1, Pp 1-11 (2019)

Abstract Background The androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60–80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors. Androgen tre

Externí odkaz: https://doaj.org/article/7ef146cc6971484fbc4ebd6c88f2c0e4

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98

Autor: Alkner, S, Jensen, M-B, Rasmussen, B B, Bendahl, P-O, Fernö, M, Rydén, L, Mouridsen, H, Hoyer, Ute

Publikováno v: Breast Cancer Research and Treatment
Alkner, S, Jensen, M-B, Rasmussen, B B, Bendahl, P-O, Fernö, M, Rydén, L, Mouridsen, H, Danish Breast Cancer Cooperative Group & Hoyer, U 2017, ' Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer : the Danish cohort of BIG 1-98 ', Breast Cancer Research and Treatment, vol. 166, no. 2, pp. 481-490 . https://doi.org/10.1007/s10549-017-4416-0

PURPOSE: To evaluate the estrogen receptor coactivator amplified in breast cancer 1 (AIB1) as a prognostic marker, as well as a predictive marker for response to adjuvant tamoxifen and/or aromatase inhibitors, in early estrogen receptor-positive brea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f6ed275c45dc8bdb0ec7ef8e15ef17e
http://europepmc.org/articles/PMC5668343

Aromatase inhibitors versus tamoxifen in early breast cancer

Autor: Dowsett, M, Forbes, JF, Bradley, R, Ingle, J, Aihara, T, Bliss, J, Boccardo, F, Coates, A, Coombes, RC, Cuzick, J, Dubsky, P, Gnant, M, Kaufmann, M, Kilburn, L, Perrone, F, Rea, D, Thuerlimann, B, Van de Velde, C, Pan, H, Peto, R, Davies, C, Gray, R, Baum, M, Buzdar, A, Sestak, I, Markopoulos, C, Fesl, C, Jakesz, R, Colleoni, M, Gelber, R, Regan, M, Von Minckwitz, G, Snowdon, C, Goss, P, Pritchard, K, Anderson, S, Costantino, J, Mamounas, E, Ohashi, Y, Watanabe, T, Bastiaannet, E

Publikováno v: Lancet, 386(10001), 1341-1352. Elsevier Science
Lancet, 386(10001), 1341-1352. Elsevier Limited
2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer : patient-level meta-analysis of the randomised trials ', The Lancet, vol. 386, no. 10001, pp. 1341-52 . https://doi.org/10.1016/S0140-6736(15)61074-1
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) & Clarke, M 2015, ' Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials ', Lancet, vol. 386, no. 10001, pp. 1341–1352 . https://doi.org/10.1016/S0140-6736(15)61074-1
Lancet, 386(10001), 1341-1352
LANCET, 386(10001), 1341-1352. ELSEVIER SCIENCE INC

Background The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.Methods We undertook meta-analyses of individual data on 31 920 postmenopausal women with oestrogen-receptor-posit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da30ef303de9fc912c17006c2a3e2207
https://research.rug.nl/en/publications/3b7ca819-e3b6-436c-8dbb-6161f6850fb2

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98

Autor: Beat Thuerlimann, Dieter Koeberle

Publikováno v: Breast Cancer Research and Treatment

The BIG 1-98 trial is a large, randomized, independently conducted clinical trial designed to compare the efficacy of upfront letrozole versus tamoxifen monotherapy and to compare sequential or up-front use of letrozole and/or tamoxifen as an early a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d5fafe08469b9aef1b7867391d4bf4b
http://europepmc.org/articles/PMC2001218

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.